rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
8
|
pubmed:dateCreated |
2010-12-14
|
pubmed:abstractText |
HCV is the main causative agent of chronic liver disease, which could progress to liver cirrhosis and hepatocellular carcinoma. By using a recently developed genome-length HCV RNA replication reporter assay system, we found that hydroxyurea (HU), an inhibitor of DNA synthesis, inhibited HCV RNA replication.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
2040-2058
|
pubmed:author |
pubmed-author:IkedaMasanoriM,
pubmed-author:KatoNobuyukiN,
pubmed-author:KondoMasaakiM,
pubmed-author:MaedaShinS,
pubmed-author:MiyajimaEijiE,
pubmed-author:MorimotoManabuM,
pubmed-author:MoritaSatoshiS,
pubmed-author:NozakiAkitoA,
pubmed-author:NumataKazushiK,
pubmed-author:SugimoriKazuyaK,
pubmed-author:TanakaKatsuakiK
|
pubmed:issnType |
Electronic
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1179-83
|
pubmed:meshHeading |
pubmed-meshheading:21149925-Administration, Oral,
pubmed-meshheading:21149925-Aged,
pubmed-meshheading:21149925-Female,
pubmed-meshheading:21149925-Hepacivirus,
pubmed-meshheading:21149925-Hepatitis C, Chronic,
pubmed-meshheading:21149925-Humans,
pubmed-meshheading:21149925-Hydroxyurea,
pubmed-meshheading:21149925-Japan,
pubmed-meshheading:21149925-Male,
pubmed-meshheading:21149925-Middle Aged,
pubmed-meshheading:21149925-Nucleic Acid Synthesis Inhibitors,
pubmed-meshheading:21149925-RNA, Viral,
pubmed-meshheading:21149925-Virus Replication
|
pubmed:year |
2010
|
pubmed:articleTitle |
Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients.
|
pubmed:affiliation |
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. akino@yokohama-cu.ac.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|